Prostaglandin analogue with timolol fixed-dose combination eye drops for treatment of open-angle glaucoma or ocular hypertension

Published on 04 Jun 2024
Last Updated on 04 Jun 2024

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has recommended:

• Latanoprost/timolol 0.005%/0.5% eye drops

in line with its registered indication for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension, in view of acceptable price proposal from the manufacturer.

Funding status

Latanoprost/timolol 0.005%/0.5% eye drops is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

SDL subsidy does not apply to:

• bimatoprost/timolol 0.03%/0.5% eye drops;

• tafluprost/timolol 0.0015%/0.5% eye drops; and
  

• travoprost/timolol 0.004%/0.05% eye drops

in view of unacceptable price proposals from the manufacturers.

Prostaglandin analogue with timolol fixed-dose combination eye drops for treatment of open-angle glaucoma or ocular hypertension (Published 4 Jun 24) [PDF, 109 KB]